C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody (APC)

Background

CLEC9A, also known as C-type lectin domain family 9 member A or DNGR-1 (Dendritic Cell Natural Killer Lectin Group Receptor 1), is an immune receptor primarily expressed on a subset of dendritic cells (DCs) and certain populations of macrophages. CLEC9A is part of the C-type lectin receptor (CLR) family, which is known for its role in recognizing carbohydrate structures on pathogens, triggering immune responses, and presenting antigens to T cells. However, CLEC9A is unique within this family for its specialized function in detecting necrotic cells and facilitating the cross-presentation of antigens from dead cells. This capability enables CLEC9A to bridge innate and adaptive immunity, playing a significant role in immune responses to infections, cancer, and tissue injury.The receptor's ability to recognize damaged cells, rather than simply pathogens, underscores its importance in contexts such as infection, cancer immunology, and autoimmunity. CLEC9A has therefore gained interest for its potential applications in vaccine development and immunotherapy. Its expression is mainly restricted to CD8+ DCs and their human equivalent, BDCA3+ DCs, which are specialized for cross-presentation, making CLEC9A a critical component in inducing CD8+ T cell responses.